1. Canobbio L, Cannata D, Miglietta L, Boccardo F: Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res 15:2687–2690, 1995
2. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV: Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21:181–192, 1992
3. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, Osborne CK: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418–1423, 1989
4. Van Den Berg CL, Stroh C, Hilsenbeck SG, Weng C-N, McDermott MJ, Cox GN, Yee D: Polyethylene glycol conjugated insulin-like growth factor binding protein inhibits growth of breast cancer in athymic mice. Eur J Cancer 33:1108–1113, 1997
5. Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, Maddux B, Goldfine ID, Vigneri R: Overexpression of membrane glycoprotein PC-1 in MDA-MB-231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Mol Endocrinol 10:1318–1326, 1996